Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michel Nussenzweig
Rockefeller University, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Frontier Biotechnologies
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
See attachment
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir
Project Narrative Combination antiretroviral therapy (ART) is highly successful in suppressing viral replication and preventing disease progression, however, it does not eradicate HIV-1. Standard ART does not fully restore health or a normal immune status in HIV-infected individuals and co-morbidities such as cardiovascular disease and cognitive impairment may occur. Efforts to identify strategies to eradicate HIV-1 infection are critical.
Filed on February 13, 2018.
Tell us what you know about Michel Nussenzweig's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Michel Nussenzweig”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michel Nussenzweig | Rockefeller University | Conflict of Interest | Frontier Biotechnologies | $60,000 - $79,999 |
| Michel Nussenzweig | Rockefeller University | Conflict of Interest | Celldex Therapeutics | $10,000 - $19,999 |
| Michel Nussenzweig | Rockefeller University | Conflict of Interest | Frontier Biotechnologies | $100,000 - $149,999 |
| Michel Nussenzweig | Rockefeller University | Conflict of Interest | Celldex Therapeutics | $400,000 - $449,999 |
| Michel Nussenzweig | Rockefeller University | Conflict of Interest | Frontier Biotechnologies | $500,000 - $549,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.